Expert Perspectives in Retinal Diseases

Dr. Sheth is being compensated by Genentech. This program is sponsored by Genentech USA, Inc.

Treating diabetic macular edema (DME)

Dr. Veeral Sheth presents the case of a patient with DME who was successfully treated with first-line VABYSMO® (faricimab-svoa).

In this video you will see:

An overview of key data from the YOSEMITE, RHINE, and RHONE-X clinical trials
What starting treatment with VABYSMO early looks like
Drying outcomes associated with VABYSMO treatment*

Patient experiences may vary.
*Reductions in central subfield thickness (CST) over time were prespecified secondary endpoints. Reductions in CST were observed across all treatment arms throughout the six Phase 3 studies in nAMD, DME, and RVO.¹

INDICATIONS
VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion (RVO).

IMPORTANT SAFETY INFORMATION

Contraindications
VABYSMO is contraindicated in patients with ocular or periocular infection, in patients with active intraocular inflammation, and in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO.

Warnings and Precautions

Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management.
Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.
There is a potential risk of arterial thromboembolic events (ATEs) associated with VEGF inhibition.
Retinal vasculitis and/or retinal vascular occlusion have been reported. Patients should be instructed to report any change in vision without delay.

Adverse Reactions
The most common adverse reactions (≥5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information in the full VABYSMO Prescribing Information.

References: 1. VABYSMO [package insert]. South San Francisco, CA: Genentech, Inc; 2026.

M-US-00033150(v1.0) 08/26